Year: 2024
Type: article
Abstract: Biomarkers play a crucial role in advancing our understanding of Alzheimer's disease (AD). These measurable indicators enable the detection of the presence and progression of the disease at earlier stages, therefore improving patient outcomes and providing opportunities for timely intervention and more personalized treatment plans.1 This series aims to provide a forward-thinking perspective on the current state of biomarker research and the challenges we face in implementing these tools in clinical practice and clinical trials.
Source: EBioMedicine
Author: Juan Fortea
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $5,000
Funders: GlaxoSmithKline, Fundació d'Investigació Sant Pau, UK Research and Innovation, National Institute for Health and Care Research, British Heart Foundation, Department of Health and Social Care, Kidney Research UK, Cystic Fibrosis Trust, Diabetes UK, Asthma and Lung UK, University College London, European Commission, Public Health England, Generalitat de Catalunya, Fundación Tatiana Pérez de Guzmán el Bueno, Versus Arthritis, Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas, Blood Cancer UK, National Institutes of Health, Horizon 2020 Framework Programme, Manchester Biomedical Research Centre, Medical Research Council, Engineering and Physical Sciences Research Council, Instituto de Salud Carlos III, Innovate UK, Horizon 2020, European Regional Development Fund, Departament de Salut, Generalitat de Catalunya, NIHR Leicester Biomedical Research Centre, National Institute on Aging
Awards: Interacción de la inflamación del sistema nervioso periférico y central en la enfermedad de Alzheimer y el síndrome de Down, G1178615512, G1483213741, The role of double-stranded RNA in pulmonary vascular remodelling, DS-ARC: A Remote Digital Cognitive Assessment for Down Syndrome-Associated Alzheimer's Disease, G1653817416, G1798610363, G1838929904, G1896610820, G2120928055, G2150449093, The Role of Inflammation and NGF Dysfunction in the Evolution of AlzheimerDisease Pathology in Down syndrome, G2306515209, PHOSP-COVID Post-hospitalisation COVID-19 study: a national consortium to understand and improve long-term health outcomes, G2628364946, MRC Transition Support CSF John Blaikley, G3012247180, G306754036, The UK Interstitial Lung Disease Long-COVID19 study (UKILD-Long COVID): understanding the burden of Interstitial Lung Disease in Long COVID., Research Excellence (round 3), G3342877126, Developing a biomarker guided strategy to treat patients with pulmonary fibrosis, Caracterización de la inflamación relacionada con amiloide: nuevos marcadores inflamatorios y su impacto en la macroestructural y microestructura cortical en la enfermedad de Alzheimer preclínica y prodrómica, G3662074923, G3930387024, G434337789, G4386455716, G4411034795, Clinical trials to prevent Alzheimer's Disease in Down Syndrome, G4595141750, G4937468798, G4976874386, G5428408597, Maths DTP 2021-22 The University of Manchester, G5918494183, G6049260834, G611400891, G6555716666, G6882471458, G6891149899, The clinical and cost-effectiveness of contemporary diagnostics for patients with suspected Hospital-Acquired Pneumonia (HAP)., G699656635, G7531143628, Tau pathology in Down syndrome and Alzheimer's, G7732978665, G8060037268, G8067524069, G8415457339, Biological Correlates of Alzheimer in Down Syndrome., G8824911526, G8858395165, G968800864
OpenAlex ID: W4403087826